Clinical Trial Update: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing the efficacy and safety of remibrutinib versus teriflunomide in relapsing multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Remibrutinib (remibrutinib)
• Teriflunomide (teriflunomide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING